Advia centaur cp

All biochemical tests were done by photometric assays (BT 2000) using Pars kit (Tehran, Iran). TPO-Ab, PTH, and TSH were measured by chemiluminescent immunoassay method (Advia Centaur CP, Siemens Healthcare Diagnostic Inc., USA).
Vitamin D measured by enzyme-linked immunosorbent assay kit (Immunodiagnostic Systems Limited, UK).

A 10-ml whole blood was collected from each participant and separated into multiple aliquots of plasma and serum for analysis including miRNA estimation. Plasma for miRNA estimation was stored at ‒80° until analysis, however, rest of the analysis were performed immediately. The Plasma glucose (GOD POD method, Beckman Coulter AU480, Japan), glycosylated hemoglobin (HPLC method, Bio-Rad, Model Variant Turbo II, and India), serum lipid profiling, including serum cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglyceride estimations using a Chemiluminescence Immunoassay (Siemens, Model EXL with LM 1 and 2, Germany) and plasma insulin was measured by electro chemiluminescence (ADVIA Centaur CP, Siemen's Healthineers, India). Insulin resistance and beta cell function (HOMA-IR and HOMA-%B) were assessed by the homeostatic method using standard formulae for calculation.[7 (link)]

The primary outcomes analyzed in the present study were perioperative changes in the concentrations of the serum markers of myocardial injury, including TnI, CK and CK-MB. Briefly, arterial blood samples (3 ml for each time point) of the patients were collected from the radial artery or from the arterial catheters during CPB at the following time points: Baseline (prior to the start of the CPB procedure), prior to aortic cannulation, 30 min prior to the placement of the aortic cross-clamp at the time of releasing the aortic cross-clamp, and 120 min after the release of the aortic cross-clamp. The levels of the markers of myocardial injury were measured using the Roche Biochemical Analyzer (ADVIA centaur-CP; Siemens AG, Munich, Germany) according to the manufacturer's instructions. The secondary outcomes analyzed were the changes in the levels of the hemodynamic parameters, including HR, MAP and central venous pressure (CVP), during the surgery and during the 12-h ICU follow-up. In addition to the abovementioned parameters, other related clinical outcomes were also evaluated, including the characteristics of CPB, usage of vasoactive medications, rebeating status of the heart and the incidence of postoperative adverse events.

All biochemical tests were done by photometric assays (BT 2000) using Pars kit (Tehran, Iran). TPO-Ab, insulin, PTH, and TSH were measured by chemiluminescent immunoassay method (Advia centaur CP, Siemens Healthcare Diagnostic Inc., USA).
HbA1c was measured by high-performance liquid chromatography (Arkray, Adams Japan). Vitamin D measured by enzyme-linked immunosorbent assay kit (immunodiagnostic system limited, UK).